Avichai Shimoni

List of Publications by Citations

169 papers	3,241 citations	33 h-index	54 g-index
179 ext. papers	3,852 ext. citations	3.9 avg, IF	4.88 L-index

#	Paper	IF	Citations
169	Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. *Leukemia*, **2006**, 20, 322-8	10.7	257
168	Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. *Blood*, **2005**, 105, 4532-9	2.2	206
167	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. *British Journal of Haematology*, **2000**, 111, 18-29	4.5	160
166	Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. *Journal of Clinical Oncology*, **2013**, 31, 3549-56	2.2	116
165	Early and late hematologic toxicity following CD19 CAR-T cells. *Bone Marrow Transplantation*, **2019**, 54, 1643-1650	4.4	114
164	Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. *Blood*, **2004**, 104, 3361-3	2.2	96
163	Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. *Biology of Blood and Marrow Transplantation*,	4.7	94
162	Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. *Leukemia*, **2007**, 21, 2109-16	10.7	85
161	A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. *Cancer*, **2012**, 118, 4706-14	6.4	84
160	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. *Journal of Clinical Oncology*, **2015**, 33, 3144-51	2.2	83
159	Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. *Blood*, **2004**, 103, 4056-61	2.2	82
158	Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. *Leukemia*, **2005**, 19, 7-12	10.7	77
157	Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. *Experimental Hematology*, **2009**, 37, 791-8	3.1	75
156	Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. *British Journal of Haematology*, **2003**, 122, 457-64	4.5	68
155	The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. *Clinical Cancer Research*, **2014**, 20, 469-79	12.9	67
154	Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. *Experimental Hematology*, **2007**, 35, 534-40	3.1	63
153	High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. *Haematologica*, **2008**, 93, 455-8	6.6	53

152	Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Biology of Blood and Marrow* [illegible]	4.7	46
151	Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. *Journal of Clinical Immunology*, **2012**, 32, 173-88	5.7	45
150	Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 117-23	4.7	45
149	Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced. *Biology of Blood and Marrow Transplantation*, **2004**, 10, 484-93	4.7	45
148	Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced. *Leukemia*, **2013**, 27, 829-35	10.7	43
147	Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. *Leukemia and Lymphoma*, **2007**, 48, 2352-9	1.9	43
146	Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. *Blood*, **2010**, 115, 2319-28	2.2	42
145	Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. *Cancer*, **2010**, 116, 3621-30	6.4	42
144	Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. *Best Practice and Research in Clinical Haematology*, **2011**, 24, 369-79	4.2	41
143	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. *Journal of Hematology and Oncology*, **2016**, 9, [illegible]	22.4	40
142	Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. *Cancer*, **2015**, 121, 863-71	6.4	37
141	Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. *Bone Marrow Transplantation*, **2008**, 41, 355-61	4.4	37
140	External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. *Blood Advances*, **2019**, 3, 1881-1890	7.8	37
139	Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 58-65	4.7	36
138	Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. *Bone Marrow Transplantation*, **2012**, 47, 1274-82	4.4	36
137	Second Malignancies after Hematopoietic Stem Cell Transplantation. *Current Treatment Options in Oncology*, **2018**, 19, 9	5.4	34
136	Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1087-1094	4.7	33
135	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. *Blood Advances*, **2017**, 1, 669-680	7.8	30

134	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*, **2015**, 100, 683-9	6.6	29
133	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 751-757	4.7	28
132	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. *Oncotarget*, **2018**, 9, 3379-3393	3.3	28
131	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. *Leukemia*, **2019**, 33, 230-239	10.7	26
130	The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. *Clinical Cancer Research*, **2017**, 23, 1733-1747	12.9	26
129	Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Cancer*, **2017**, 123, 2671-2679	6.4	25
128	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*, **2014**, 99, 1380-6	6.6	25
127	Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. *Clinical and Developmental Immunology*, **2012**, 2012, 753407		24
126	Anti-47 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. *Bone Marrow Transplantation*, **2019**, 54, 987-993	4.4	24
125	Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. *Experimental Hematology*, **2003**, 31, 428-34	3.1	23
124	Regulatory T cells in allogeneic stem cell transplantation. *Clinical and Developmental Immunology*, **2013**, 2013, 608951		22
123	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. *PLoS ONE*, **2016**, 11, e0150637	3.7	20
122	Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. *European Journal of Haematology*, **2019**, 103, 402-409	3.8	18
121	Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. *European Journal of Haematology*, **2012**, 89, 201-13	3.8	18
120	The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. *Leukemia*, **2018**, 32, 1787-1794	10.7	16
119	Cytomegalovirus retinitis in HIV-negative patients: a practical management approach. *Ophthalmology*, **2015**, 122, 866-868.e3	7.3	15
118	Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. *Molecular Carcinogenesis*, **2020**, 59, 736-744	5	15
117	Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 2072-5	4.7	14

116	Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. *Leukemia and Lymphoma*, **2007**, 48, 2110-20	1.9	13
115	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. *Blood Cancer Journal*, **2019**, 9, 88	7	13
114	Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. *Psychophysiology*, **2004**, 3, 242-8		13
113	Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies. *Oncogenesis*, **2018**, 7, 51	6.6	12
112	A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation. *Journal of Immunotherapy*, **2010**, 33, 326-33	5	12
111	Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning. *Acta Haematologica*, **2004**, 112, 93-104	2.7	12
110	CAR T cells induce a complete response in refractory Burkitt Lymphoma. *Bone Marrow Transplantation*, **2018**, 53, 1583-1585	4.4	12
109	Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 277-283	4.7	11
108	Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. *Journal of Leukocyte Biology*, **2014**, 95, 677-88	6.5	11
107	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. *Current Research in Translational Medicine*, **2020**, 68, 17-22	3.7	11
106	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. *British Journal of Haematology*, **2019**, 186, 767-776	4.5	10
105	Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1685-1691	4.7	10
104	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2251-2260	4.7	10
103	Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. *Leukemia*, **2020**, 34, 1939-1942	10.7	9
102	BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation. *Blood*, **2010**, 116, 2260-2260	2.2	9
101	The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. *American Journal of Hematology*, **2017**, 92, 259-268	7.1	8
100	Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma. *Seminars in Nuclear Medicine*, **2016**, 46, 119-25	5.4	8
99	Monoclonal antibody-based immunotherapy for multiple myeloma. *Immunotherapy*, **2012**, 4, 919-38	3.8	8

98	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. *American Journal of Hematology*, **2017**, 92, 1011-1019	7.1	7
97	Conditioning **2019**, 99-107		7
96	LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2020**, 55, 1736-1743	4.4	6
95	The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. *Biochemical Pharmacology*, **2019**, 168, 412-428	6	6
94	A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan. *Rapid Communications in Mass Spectrometry*, **2019**, 33, 1635-1642	2.2	6
93	Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. *Blood*, **2019**, 134, 3234-3234	2.2	6
92	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. *British Journal of Haematology*, **2021**,	4.5	6
91	Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. *Journal of Hematology and Oncology*, **2020**, 13, 158	22.4	6
90	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. *Cancer*, **2021**, 127, 1246-1259	6.4	6
89	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. *Bone Marrow Transplantation*, **2021**, 56, 1134-1143	4.4	6
88	Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. *Cancer Treatment and Research*, **2002**, 110, 113-36	3.5	6
87	Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Oncologist*, **2015**, 20, 50-5	5.7	5
86	Second malignancies after allogeneic stem cell transplantation with reduced-intensity conditioning: is the incidence reduced?. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1669-70	4.7	5
85	Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. *Journal of Clinical Apheresis*, **2017**, 32, 295-301	3.2	5
84	Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia. *Oncotarget*, **2017**, 8, 418-429	3.3	5
83	Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis. *Bone Marrow Transplantation*, **2020**, 55, 147-156	4.4	5
82	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. *Leukemia and Lymphoma*, **2021**, 62, 1692-1701	1.9	5
81	The role of stem-cell transplantation in the treatment of marginal zone lymphoma. *Best Practice and Research in Clinical Haematology*, **2017**, 30, 166-171	4.2	4

80	Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13 Suppl 2, S330-48	2	4
79	Repeated Courses of Orally Administered Fecal Microbiota Transplantation for the Treatment of Steroid Resistant and Steroid Dependent Intestinal Acute Graft Vs. Host Disease: A Pilot Study (NCT 03214289). *Blood*, **2018**, 132, 2121-2121	2.2	4
78	Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease. *Oncotarget*, **2017**, 8, 90748-90765	3.3	4
77	Haploidentical stem-cell transplant: the challenge of immune reconstitution. *Leukemia and Lymphoma*, **2013**, 54, 2579-80	1.9	3
76	Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring. *Leukemia and Lymphoma*, **2010**, 51, 2154-6	1.9	3
75	Combination of Rituximab with Initial Chemotherapy Improves Outcome of Primary Mediastinal B-Cell Lymphoma: A Retrospective Analysis of a Single Institution Cohort. *Blood*, **2007**, 110, 1283-1283	2.2	3
74	Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.. *Blood*, **2010**, 116, 3473-3473	2.2	3
73	Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT. *Blood*, **2013**, 122, 545-545	2.2	3
72	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. *Leukemia*, **2021**, 35, 2232-2242	10.7	3
71	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma.. *Transplantation and Cellular Therapy*, **2022**,		3
70	Risk stratification of patients with multiple myeloma prior to autologous stem cell transplant: what is the role of serum ferritin levels?. *Leukemia and Lymphoma*, **2014**, 55, 2419-20	1.9	2
69	Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?. *Leukemia and Lymphoma*, **2009**, 50, 1395-6	1.9	2
68	Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: The Role of Dose-Intensity.. *Blood*, **2005**, 106, 47-47	2.2	2
67	Nilotinib Exhibits an in Vitro Antiviral Activity Against Human Cytomegalovirus (HCMV): Potential Clinical Applications. *Blood*, **2012**, 120, 4666-4666	2.2	2
66	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. *British Journal of Haematology*, **2021**, 195, 417-428	4.5	2
65	Combined escBEACOPP-ABVD Therapy for Advanced Hodgkin Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan.. *Blood*, **2007**, 110, 2319-2319	2.2	1
64	Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study.. *Blood*, **2008**, 112, 1965-1965	2.2	1
63	The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients. *Blood*, **2013**, 122, 3275-3275	2.2	1

62	Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia. *Oncotarget*, **2020**, 11, 2233-2245	3.3	1
61	ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.. *Annals of Hematology*, **2022**, 101, 309-316	3	1
60	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. *Annals of Hematology*, **2021**, 1	3	1
59	Ibritumomab Tiuxetan (Zevalin) in the Conditioning Regimen for Autologous and Reduced-Intensity Allogeneic Stem-Cell Transplantation in Patients with Chemo-Refractory Non-Hodgkin Lymphoma.. *Blood*, **2005**, 106, 1131-1131	2.2	1
58	Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen. *Blood*, **2019**, 134, 4489-4489	2.2	1
57	A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage	2.2	1
56	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. *Blood Cancer Journal*, **2021**, 11, 88	7	1
55	A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia. *European Journal of Haematology*, **2021**, 106, 260-266	3.8	1
54	Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.. *Annals of Hematology*, **2022**, 101, 581	3	0
53	Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients. *Blood*, **2021**, 138, 910-910	2.2	0
52	Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based Model Using The Data Set of The Acute Leukemia Working Party (ALWP) Of The EBMT. *Blood*, **2013**, 122, 409-409	2.2	0
51	Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. *Acta Haematologica*, **2021**, 144, 613-619	2.7	0
50	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. *Bone Marrow Transplantation*, **2021**, 56, 2690-2696	4.4	0
49	Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation. *International Journal of Hematology*, **2021**, 114, 363-372	2.3	0
48	Immunotherapy for B-cell lymphoma. *Leukemia and Lymphoma*, **2010**, 51, 7-9	1.9	
47	Mobilization regimens prior to stem-cell collection in patients with lymphoma: how to choose?. *Leukemia and Lymphoma*, **2007**, 48, 1888-90	1.9	
46	Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol. *Blood*, **2020**, 136, 28-29	2.2	
45	A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2020**, 136, 5-6	2.2	

44	ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy. *Blood*, **2021**, 138, 3392-3392	2.2
43	Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. *Blood*, **2021**, 138, 3390-3390	2.2
42	Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma. *Blood*, **2021**, 138, 1195-1195	2.2
41	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study. *Blood*, **2021**, 138, 3962-3962	2.2
40	Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.. *Blood*, **2004**, 104, 980-980	2.2
39	Abdominal CT in the Clinical Evaluation of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract: Diffuse Small Intestine Involvement Is Associated with Severity and Outcome.. *Blood*, **2004**, 104, 5073-5073	2.2
38	Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.. *Blood*, **2004**, 104, 1646-1646	2.2
37	Persistent Mixed Chimerism in Plasma Cells Following Allogeneic Stem-Cell Transplantation in Patients with Acute Leukemia Is a Surrogate Marker for Leukemia Relapse.. *Blood*, **2005**, 106, 2749-2749	2.2
36	Spontaneous Pregnancy and Fertility Preservation Program in Women Undergoing High Dose Chemotherapy for Hematological Malignancies.. *Blood*, **2005**, 106, 1114-1114	2.2
35	BCL6 Is Regulated by p53 through a Response Element Frequently Disrupted in B-Cell Non-Hodgkin Lymphoma.. *Blood*, **2005**, 106, 158-158	2.2
34	Prolongation of Post Relapse and Overall Survival in Patients with Multiple Myeloma by Salvage Strategy with the Combination of Thalidomide and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation Based on the Nature of Disease Progression after Autologous Bone Marrow Transplantation.. *Blood*, **2005**, 106, 3494-3494	2.2
33	Nonmyeloablative Stem Cell Transplantation in the Treatment of Hematologic Malignancies **2006**, 351-360	
32	No Evidence for Increased Transplant Related Complications in Ph+ Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia with Prior Treatment with Dasatinib.. *Blood*, **2006**, 108, 2975-2975	2.2
31	Towards Stopping Imatinib Therapy under the Umbrella of Interferone: Alpha-Interferone Improves Molecular Response in CML Patients with Imatinib Induced Complete Cytogenetic Remission: An Early Observation from a Study of Pegylated Interferone in the Set up of Minimal Residual Disease.. *Blood*, **2006**, 108, 4709-4709	2.2
30	Comparison between Two Reduced-Intensity Conditioning Regimens Prior to Allogeneic Stem Cell Transplantation: Fludarabine and Melphalan Is Associated with Higher Incidence of Acute Graft-Versus-Host Disease and Non-Relapse Mortality and Lower Incidence of Relapse Than Fludarabine and Busulfan.. *Blood*, **2006**, 108, 2947-2947	2.2
29	Donor C3435T Polymorphism in the Multidrug Resistance 1 (MDR1) Gene Is Associated with the Incidence of Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.. *Blood*, **2006**, 108, 2868-2868	2.2
28	Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).. *Blood*, **2007**, 110, 1650-1650	2.2
27	High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM).. *Blood*, **2007**, 110, 1080-1080	2.2

26	Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.. *Blood*, **2007**, 110, 1668-1668	2.2
25	Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.. *Blood*, **2007**, 110, 2002-2002	2.2
24	Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-Induced ER Stress and Cell Death Via HSP70 and LAMP3 Down-Regulation: Novel Therapeutic Target for Multiple Myeloma. *Blood*, **2017**, 130, 804-804	2.2
23	Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis. *Blood*, **2019**, 134, 1989-1989	2.2
22	Non Interventional Prospective Clinical Study on Peripheral Blood Stem Cell Mobilization in Patients with Relapsed Lymphomas. *Blood*, **2014**, 124, 3852-3852	2.2
21	Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric. *Blood*, **2014**, 124, 1224-1224	2.2
20	S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways. *Blood*, **2014**, 124, 4707-4707	2.2
19	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. *Blood*, **2014**, 124, 1216-1216	2.2
18	Anti-Human T-Lymphocyte Immunoglobulin (ATG)-Induced T Regulatory Cells and Their Soluble Factors Suppress T Cell Proliferation: Potential Role in Allogeneic Stem Cell Transplantation. *Blood*, **2015**, 126, 1889-1889	2.2
17	Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An-ALWP-EBMT Survey.. *Blood*, **2009**, 114, 195-195	2.2
16	Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing Multiple Myeloma: Long-Term Follow-up.. *Blood*, **2009**, 114, 3359-3359	2.2
15	Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting.. *Blood*, **2010**, 116, 1300-1300	2.2
14	Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation. *Blood*, **2010**, 116, 2314-2314	2.2
13	Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning,. *Blood*, **2011**, 118, 4096-4096	2.2
12	CXCR4 Promotes the Tumorogenicity of Multiple Myeloma, Including Increased Motility, Clonogenicity, up-Regulation of VLA-4, Protection From Chemotherapy and Aggressive Tumor Development In Vivo. *Blood*, **2011**, 118, 1801-1801	2.2
11	Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.. *Blood*, **2012**, 120, 2629-2629	2.2
10	Assessment of the Effect of Nilotinib (Tasigna) Maintenance Therapy After Allogeneic Stem Cell Transplantation in Patients with Advanced CML and Ph+ ALL On Immune Reconstitution and Lymphocyte Function. *Blood*, **2012**, 120, 4478-4478	2.2
9	A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease. *Blood*, **2012**, 120, 1690-1690	2.2

List of Publications

8	Treatment of Relapsed AML and MDS After Allogeneic Stem Cell Transplantation: A Second Transplant From a Different Donor May Be the Most Effective Option. *Blood*, **2012**, 120, 1963-1963	2.2
7	Missing HLA C Group 1 Ligand In Patients With AML and MDS Is Associated With Reduced Risk Of Relapse After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning. *Blood*, **2013**, 122, 4634-4634	2.2
6	Chemotherapy Dose Adjustment For Obese Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Survey On Behalf Of The ALWP Of The EBMT. *Blood*, **2013**, 122, 4535-4535	2.2
5	Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later. *Blood*, **2013**, 122, 4635-4635	2.2
4	Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity. *Lancet Haematology,the*, **2020**, 7, e4-e5	14.6
3	Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors. *Bone Marrow Transplantation*, **2021**, 56, 451-456	4.4
2	How to predict response to treatment and outcome in patients with gastro-intestinal acute GVHD; Can F-FDG-PET scanning help?. *Transplantation and Cellular Therapy*, **2021**, 27, 525-526	
1	Non-myeloablative stem-cell transplantation in the treatment of malignant and non-malignant disorders. *Israel Medical Association Journal*, **2002**, 4, 272-9	0.9